UNLIMITED TURBO SHORT - ELI LILLY & CO | Market Closed - Borsa Italiana 04:04:59 2024-07-12 pm EDT | ||
| 8.53 EUR | -12.96% |
|
| Current month | -30.50% | ||
| 1 month | -45.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 8.75 | -10.71% |
| 24-07-11 | 9.8 | +4.37% |
| 24-07-10 | 9.39 | -5.72% |
| 24-07-09 | 9.96 | -13.62% |
| 24-07-08 | 11.53 | -1.71% |
Real-time Borsa Italiana
Last update July 12, 2024 at 04:04 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| P23HR4 | |
| ISIN | NLBNPIT23HR4 |
| Date issued | 2024-05-29 |
| Strike | 1,020 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.65 € |
|---|---|
| Lowest since issue | 8.42 € |
| Spread | 0.3 € |
| Spread % | 3.45% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
948.4
USD
Average target price
894.8
USD
Spread / Average Target
-5.65%
- Stock Market
- Certificates
- P23HR4 Certificat
